Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer

To the Editor In their recent Original Investigation in JAMA Oncology, Gettinger et al¹ demonstrated the inefficacy of the nivolumab plus ipilimumab treatment regimen in improving clinical outcomes of stage IV pretreated squamous non–small cell lung cancer without checkpoint inhibitor therapy. This trial provides new insights on the unfavorable role of the nivolumab plus ipilimumab treatment regimen over monotherapy in such patients. However, we have several concerns.